HETEROCYCLES, Vol. 83, No. 5, 2011, pp. 1145 - 1151. © The Japan Institute of Heterocyclic Chemistry Received, 15th February, 2011, Accepted, 15th March, 2011, Published online, 25th March, 2011 DOI: 10.3987/COM-11-12175

FEASIBLE SYNTHESIS OF THE GPR40 ANTAGONIST BY CONTRUCTING 2-THIOURACIL RING *VIA* ACID MEDIATED CYCLIZATION

Yongfeng Zhao¹ and Jiayu Liao^{1,2,*}

¹Department of Bioengineering, Bourns College of Engineering, and ²Institute for Integrative Genome Biology, University of California at Riverside, 900 University Avenue, Riverside, CA 92521

*Corresponding author. Tel: 951-827-6240; Fax: 951-827-6416

e-mail: jiayu.liao@ucr.edu

Abstract – GW1100 is an antagonist of GPR40 identified by high throughput screening recently. The feasible synthesis of GW1100 has been developed in mild conditions. The key step involves the cyclization of the 2-thiouracil heterocycle under acidic conditions at room temperature.

GPR40 is a G-protein coupled receptor that is highly expressed in the beta cell of pancreatic islets, and its activation by long-chain free fatty acids enhances glucose-stimulated insulin secretion.¹ The gene knockout mice of GPR40 show resistance to high fat diet-induced diabetic symptoms.² Therefore it has been identified as a possible novel target for the treatment of type 2 diabetes.

There is no clear understanding to date whether agonist and antagonist of GPR40 would provide beneficial effects for the treatment of type 2 diabetes. To learn more about the pharmacology of GPR40 and about the implications of receptor activation and inhibition, the development of a synthetic agonist and antagonist would be very helpful in GPR40 proof-of-concept studies as its functional mode.

Recently, the first selective antagonist of GPR40, GW1100, was identified by high-throughput screening (HTS).³ At first, this compound was developed as phosphodiesterase A2 inhibitor.⁴ This compound was shown to completely inhibit the enhancement of glucose-stimulated insulin secretion mediated by agonist and to partially inhibit the enhancement mediated by nature ligand (e.g. linoleic acid).

GW1100 (11) is an attractive molecular tool to further study the biological activities of GPR40 *in vitro* and *in vivo*. The structure-activity relationship (SAR) of 11 with its receptor GPR40 has not been

explored. Large scale synthesis of compound is also demanded to study the pharmacological effects of GPR40 in animals. Therefore, facile synthetic route is urgently needed to prepare **11**. However, there is no full report of synthesis of **11** in the literature.

To synthesize **11**, the key step is to construct a 2-thiouracil ring. Though there are many studies show that substituted 2-thiouracil analogue have remarkably contributed to biological and medicinal chemistry, few works have reported the synthesis of N-substituted 2-thiouracil ring, and strong basic conditions and high temperature have usually been used.⁴⁻⁶ In this work, we described the total synthesis of **11** using acidic conditions for ring closure. To the best of our knowledge, this is the first paper reporting feasible total synthesis of **11**.

The synthesis of **11** started with the inexpensive 5-bromo-2-chloropyrimidine **1** (Scheme 1). Thus, nucleophilic displacement of **1** afforded 5-bromo-2-ethoxypyrimidine **2** according to modification of procedures in the literature.^{7,8} Our method for preparation of **2**, using freshly prepared sodium ethoxide and absolute alcohol as a solvent to improve the solubility of reactant, considerably improved the yield to over 95%. The coupling reaction of **2** with ethyl acrylate was conducted in the presence of a catalytic amount of the palladium diacetate-triphenylphosphine complex. The reaction mixture was heated at 140 °C in a sealed tube to afford ethyl 3-(2-ethoxypyrimidin-5-yl)acrylate **3** in 64% yield.^{9,10} The reduction of **3** was conducted in ethanol at room temperature to give ethyl 3-(2-ethoxypyrimidin-5-yl)propionate **4** in a yield of 80%.

Compound **4** was subjected to formylation reaction using methyl formate and sodium ethoxide as a base,^{11,12} then the resultant was methylated by dimethyl sulfate to obtain ester **5** in a total yield of 53%. We found that the application of freshly prepared sodium ethoxide can depress the unexpected by-products which showed high polarity comparing to the product. Compound **5** was obtained as the mixture of 2:3 ethyl and methyl ester which was determined by ¹H NMR after isolation.



Scheme 1

As shown in Scheme 2, the resulting ester mixture **5** was hydrolyzed directly under 2 M LiOH to give crystalline acid **6** in 88% yield. The latter acid **6** was treated with oxalyl chloride in the presence of a drop of DMF to provide the acid chloride **7**.^{13,14} The acid chloride **7** was then coupled with KSCN to give the corresponding isothiocyanate derivative **8**.^{15,16} After changing the solvent into DMF, the compound **8** was reacted immediately with 4-aminobenzoate to give intermediate **9**. This intermediate then underwent next step without isolation.



Scheme 2

In the literature, strong basic conditions and high temperature have been usually applied for similar cyclization reaction.³⁻⁵ For this case (Scheme 3), we conducted ring-closure reaction under acidic conditions. After acidifying the solution of intermediate 9,¹⁷ compound 10 was synthesized in a total yield of 27% from 6. This step was the key step for the synthesis of target molecule.

Finally, compound **10** was subjected to S-alkylation with 4-flurobenzyl bromide to give target product **11** in moderate yield.⁵ The ¹H NMR match the data reported in reference 4.



In conclusion, we have developed the acid mediated-cyclization route for the synthesis of GW1100. To the best of our knowledge this is the first report of feasible synthesis of GW1100. Significantly, the route requires very mild conditions and utilizes inexpensive starting material 5-bromo-2-chloropyrimidine **1**. Application of this methodology to synthesize various pyrimidine derivatives can be explored in the future.

EXPERIMENTAL

General

The ¹H NMR and ¹³C NMR were recorded on Varian VRX 300, 400 spectrometers, and chemical shifts were expressed in parts per million (δ) relative to internal CDCl₃. Melting points were determined on Buchi Melting Point B-545 and are uncorrected.

THF, CH₂Cl₂ and toluene were distilled prior to use. DMF and MeCN was anhydrous solvent obtained from Aldrich. All other reagents and solvents were obtained from commercial sources and were used without any further purification. Reactions were routinely carried out under an atmosphere of dry argon with magnetic stirring. Flash chromatography was generally performed on silica gel. The yields were calculated after isolation.

5-Bromo-2-ethoxypyrimidine (2)

Sodium (0.220 g, 9.56 mmol) was put into dry EtOH (40 mL) under 0 °C, and the mixture was stirred at rt until the sodium disappeared. To the resulting solution, 5-bromo-2-chloropyrimidine (1.5 g, 7.5 mmol) was added. The mixture solution was stirred at rt overnight. After removing of EtOH under reduced pressure, the residue was partitioned between water and ethyl ether. The organic phase was washed with brine and dried over anhydrous Na₂SO₄. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (Hexanes : Et₂O = 5 : 2) to give compound **2** as white solid (1.44 g, 7.1 mmol, 95%). ¹H NMR (400 MHz, CDCl₃, 25 °C) δ 1.43 (t, *J* = 7.2 Hz, 3H), 4.40 (q, *J* = 7.2 Hz, 2H), 8.51 (s, 2H); ¹³C NMR (100 MHz, CDCl₃, 25 °C) δ 14.3, 64.2, 111.6, 159.5, 163.8.

Ethyl 3-(2-ethoxypyrimidin-5-yl)acrylate (3)

A mixture of **2** (0.300 g, 1.48 mmol), triphenylphosphine (0.0093 g, 0.0356 mmol), palladium (II) acetate (0.0043 g, 0.0192 mmol), ethyl acrylate (0.6 g, 5.25 mmol) and triethylamine (1 mL) were heated at 140 °C with stirring under argon for 16 h. After cooling to room temperature, the ethyl acrylate was removed and the residues were partitioned between EtOAc and water. The organic phase was washed with brine and dried over anhydrous Na₂SO₄. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (Hexanes : Et₂O = 1 : 1) to give compound **3** as white solid (0.210 g, 0.945 mmol, 64%). ¹H NMR (400 MHz, CDCl₃, 25 °C) δ 1.34 (t, *J* = 6.8 Hz, 3H), 1.45 (t, *J* = 7.2 Hz, 3H), 4.27 (q, *J* = 7.2 Hz, 2H), 4.45 (q, *J* = 6.8 Hz, 2H), 6.43 (d, *J* = 16.4 Hz, 1H), 7.56 (d, *J* = 16.4 Hz, 1H), 8.65 (s,

2H); ¹³C NMR (100 MHz, CDCl₃, 25 °C) δ 14.2, 14.3, 60.8, 64.1, 118.8, 122.1, 137.3, 158.4, 165.7, 166.2.

Ethyl 3-(2-ethoxypyrimidin-5-yl)propionate (4)

A suspension of **3** (0.210 g, 0.945 mmol) in EtOH (2 mL) and 10% Pd/C (0.012 g), triethylamine (0.2 mL) was hydrogenated at 50 psi overnight. The catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in CH₂Cl₂, washed by saturated aqueous NH₄Cl and brine respectively, and dried over anhydrous Na₂SO₄. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (Hexanes : Et₂O = 1 : 1) to give compound **4** as colorless oil (0.170 g, 0.758 mmol, 80%). ¹H NMR (400 MHz, CDCl₃, 25 °C) δ 1.23 (t, *J* = 7.2 Hz, 3H), 1.42 (t, *J* = 6.9 Hz, 3H), 2.60 (t, *J* = 6.9 Hz, 2H), 2.86 (t, *J* = 7.2 Hz, 2H), 4.25 (q, *J* = 7.2 Hz, 2H), 4.39 (q, *J* = 7.2 Hz, 2H), 8.35 (s, 2H); ¹³C NMR (100MHz, CDCl₃, 25 °C) δ 14.4, 14.7, 24.8, 35.5, 60.6, 63.5, 126.7, 159.2, 164.4, 172.2.

2-(Methoxymethylene)-3-(2-ethyoxypyrimidin-5-yl)propionic acid ethyl/methyl ester (5)

To a stirring suspension of freshly made EtONa (0.118 g, 1.74 mmol) in THF (0.5 mL) was added dropwise a solution of **4** (0.100 g, 0.446 mmol) and methyl formate (0.100 g, 0.793 mmol) in THF (0.5 mL) at 0 °C. After the mixture was stirred at rt overnight and cooled to 0 °C, the dimethyl sulfate (0.1 mL) was added slowly. After 4 h the solvent was evaporated and the residue was treated with water and extracted with EtOAc. The extracts were washed with water, dried over anhydrous Na₂SO₄. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (Hexanes : EtOAc = 1 : 1) to give compound **5** as colorless oil 2-(ethoxymethylene)-3-(2-methyoxypyrimidin-5-yl)propionic acid ethyl ester (0.030 g, 0.0945 mmol, 21%) and methyl ester (0.03 g, 0.142 mmol, 32%). ¹H NMR (400 MHz, CDCl₃, 25 °C) Ethyl ester: δ 1.25 (t, *J* = 6.9 Hz, 3H), 1.41 (t, *J* = 7.5 Hz, 3H), 3.44 (s, 2H), 3.88 (s, 3H), 4.15 (q, *J* = 7.5 Hz, 2H), 4.37 (q, *J* = 6.9 Hz, 2H), 7.37 (s, 1H), 8.37 (s, 2H); Methyl ester: δ 1.40 (t, *J* = 7.2 Hz, 3H), 3.42 (s, 2H), 3.66 (s, 3H), 3.85 (s, 3H), 4.36 (q, *J* = 7.2 Hz, 2H), 7.35 (s, 1H), 8.35 (s, 2H); ¹³C NMR (100 MHz, CDCl₃, 25 °C) δ 14.5, 23.7, 51.4, 61.7, 63.1, 109.1, 126.8, 159.0, 159.6, 163.8, 167.9.

2-(Methoxymethylene)-3-(2-ethyoxypyrimidin-5-yl)propionic acid (6)

A suspension of the ester **5** (0.23 g, 0.86 mmol) in 2 M aqueous lithium hydroxide (2 mL) was stirred at rt overnight. The resulting clear yellow solution was acidified by 1 M HCl to pH = 3 and extracted with CH₂Cl₂, and dried over anhydrous Na₂SO₄. White solid **6** (0.18 g, 0.756 mmol, 88%) was obtained after evaporation of solvent. ¹H NMR (400 MHz, CDCl₃, 25 °C) δ 1.41 (t, *J* = 7.2 Hz, 3H), 3.44 (s, 2H), 3.91 (s, 3H), 4.37 (q, *J* = 7.2 Hz, 2H), 7.48 (s, 1H), 8.39 (s, 2H).

1-(4-Ethoxycarbonylphenyl)-5-(2-ethoxypyrimidin-5-ylmethyl)-2-thiouracil (10)

To the solution of **6** (0.086 g, 0.361 mmol) in dry CH_2Cl_2 (2 mL) one drop of DMF, then oxalyl chloride (0.28 mL) was added slowly at 0 °C. After stirring at rt for 2 h, the solvent was removed and additional

toluene was added and removed in vacuum. The solid was slurried in dry MeCN (0.5 mL), and the resulting mixture was dropped into the slurry solution of KSCN (0.070 g, 0.720 mmol) in MeCN (0.2 mL) at 0 °C. After the mixture was stirred at rt for 20 h, the solvent was removed in vacuum, and the resulting solid was dissolved in DMF (0.5 mL). The resulting solution was added to the solution of ethyl 4-aminobenzoate (0.074 g, 0.448 mmol) and triethylamine (0.096 mL) in DMF (0.5 mL). After stirring at rt overnight, 2 M H₂SO₄ (4 mL) was added and the slurry solution was stirred at rt for 5 h. The resulting mixture was extracted with CH₂Cl₂ three times and the organic phase was dried over anhydrous Na₂SO₄. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (Hexanes : EtOAc = 1 : 2) to give compound **10** as pale yellow solid (0.040 g, 0.097 mmol, 27%); Melting point: 206-208 °C; ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 1.37 (m, 6H), 3.61 (s, 2H), 4.45 (m, 4H), 7.11 (s, 1H), 7.44 (d, *J* = 6.6 Hz, 2H), 8.23 (d, *J* = 6.6 Hz, 2H), 8.43 (s, 2H); ¹³C NMR (100 MHz, CDCl₃, 25 °C) δ 14.3, 14.4, 26.9, 61.5, 63.6, 118.4, 123.5, 127.4, 131.2, 141.4, 145.2, 159.4, 164.5, 165.1, 175.9; HRMS (ESI⁺) (*m/z*): [M + H]⁺ Calcd. For C₂₀H₂₁N₄O₄S: 413.1284; Found: 413.1292.

1-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5-(2-ethoxypyrimid-5-ylmethyl)pyrimidin-4one (11)

To the solution of **10** (0.040 g, 0.097 mmol) and 4-fluorobenzy bromide (0.025 g, 0.13 mmol) in CH₂Cl₂ (0.5 mL) was added the diisopropylethylamine (0.025 mL). The solution was stirred at rt overnight. After evaporation of solvent, the residue was purified by flash chromatography on silica gel (EtOAc : Hexanes = 4 : 1, then elute with EtOAc : MeOH = 10 : 1) to get **11** (0.024 g, 0.0461 mmol, 48%) as white solid; Melting point: 208-210 °C; ¹H NMR (400 MHz, CDCl₃, 25 °C) δ 1.40 (m, 6H), 3.67 (s, 2H), 4.39 (m, 6H), 6.95 (m, 3H), 7.26 (m, 2H), 7.37 (d, *J* = 8.4 Hz, 2H), 8.16 (d, *J* = 8.4 Hz, 2H), 8.45 (s, 2H); ¹³C NMR (100 MHz, CDCl₃, 25 °C) δ 14.2, 14.4, 27.8, 36.0, 61.7, 63.5, 115.5, 115.6, 121.2, 124.4, 127.4, 131.1, 131.4, 132.8, 139.5, 142.2, 159.5, 162.3, 163.6, 164.4, 164.8, 167.2; HRMS (ESI⁺) (*m/z*): [M + H]⁺ Calcd. For C₂₇H₂₆FN₄O₄S: 521.1659; Found: 521.1639.

ACKNOWLEDGEMENTS

We are grateful to Dr. Michael Pirrung for generously allowing us to use his lab facilities. We would like to thank Bioengineering department for support of this work.

REFERENCES

Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino, *Nature*, 2003, 422, 173.

- P. Steneberg, N. Rubins, R. Bartoov-Shifman, M. D. Walker, and H. Edlund, *Cell Metabolism*, 2005, 1, 245.
- C. P. Briscoe, A. J. Peat, S. C. McKeown, D. F. Corbett, A. S. Goetz, T. R. Littleton, D. C. McCoy, T. P. Kenakin, J. L. Andrews, C. Ammala, J. A. Fornwald, D. M. Ignar, and S. Jenkinson, *Br. J. Pharmacol.*, 2006, 148, 619.
- F. A. Edward, H. D. M. Bernadette, I. R. John, L. C. Andrew, and S. S. Allan, *PCT Int. Appl.*, 2000, 51; WO0068208.
- 5. E. Wyrzykiewicz and T. Pospieszny, J. Heterocycl. Chem., 2007, 44, 55.
- 6. I. Winckelmann and E. Larsen, Synthesis, 1986, 1041.
- 7. C. C. Kofink and P. Knochel, Org. Lett., 2006, 8, 4121.
- 8. D. G. Crosby and A. J. Vlitos, *Science*, 1958, **128**, 480.
- 9. R. F. Heck, J. Am. Chem. Soc., 1969, 91, 6707.
- 10. A. Wada, H. Yasuda, and S. Kanatomo, Synthesis, 1988, 771.
- T. H. Brown, R. C. Blakemore, G. J. Durant, J. C. Emmett, C. R. Ganellin, M. E. Parsons, D. A. Rawlings, and T. F. Walker, *Eur. J. Med. Chem.*, 1988, 23, 53.
- 12. T. Hjelmgaard, I. Sotofte, and D. Tanner, J. Org. Chem., 2005, 70, 5688.
- F. Micheli, A. Pasquarello, G. Tedesco, D. Hamprecht, G. Bonanomi, A. Checchia, A. Jaxa-Chamiec, F. Damiani, S. Davalli, D. Donati, C. Gallotti, M. Petrone, M. Rinaldi, G. Riley, S. Terreni, and M. Wood, *Bioorg. Med. Chem. Lett.*, 2006, 16, 3906.
- 14. C. Sun, X. Zhang, H. Huang, and P. Zhou, Bioorg. Med. Chem. Lett., 2006, 14, 8574.
- 15. T.-B. Wei, Q. Lin, Y.-M. Zhang, and W. Wei, Synth. Commun., 2004, 34, 181.
- 16. O. Hritzova, J. Cernak, P. Safar, Z. Frohlichova, and I. Csoregh, J. Mol. Struct., 2005, 743, 29.
- 17. R. Csuk and Y. v. Scholz, *Tetrahedron*, 1995, **51**, 7193.